Samsung BiologicsCDMOSamsung Targets Swiss CDMO PolyPeptide in $1.8 Billion DealConsolidation in the contract development and manufacturing organization (CDMO) sector continues to accelerate. With a bid valued at approximately US$1.8 billion for Swiss peptide specialist PolyPeptide, … more ➔
startupsBrenus adds €11M to colorectal cancer vaccine developmentFrench biotech Brenus Pharma has raised an €11 million Series A extension to complete the Phase 1 development of its lead colorectal cancer immunotherapy and advance a second programme from its pl … more ➔
TechnologiesRNA medicine enters its second actThe COVID-19 pandemic transformed RNA technologies into one of the most visible scientific breakthroughs of the decade. mRNA vaccines demonstrated unprecedented speed of development, large-scale manufacturing … more ➔
startupsSightera raises €3M to advance AI-generated molecular gluesBelgian techbio Sightera Biosciences has raised €3 million in pre-seed financing to expand its AI drug discovery platform and advance a pipeline of small molecules in oncology and fibrosis. more ➔
clinical dataGSK setback deepens P2X3 cough drug doubtsGSK has stopped developing camlipixant for refractory chronic cough after mixed Phase 3 results, adding another setback to a P2X3 drug class that has repeatedly struggled to turn biological promise into … more ➔
investmentIsomorphic megadeal lifts UK biotech funding to five-year highUK biotech companies raised £2.11 billion in equity financing in the second quarter of 2026, as a record round for Isomorphic Labs pushed venture investment to its highest level in five years. more ➔
artificial intelligenceOrakl takes on four Sanofi cancer assetsFrench techbio Orakl Oncology has secured exclusive rights to four undisclosed oncology assets from Sanofi, giving the startup an opportunity to test whether its combination of patient-derived tumour … more ➔
M&AMission Therapeutics refocuses on CNS and sells $292M kidney drug to DimerixUK biotech Mission Therapeutics has sold its Phase 2-ready acute kidney injury drug MTX652 to Australia’s Dimerix in a deal worth up to $292 million (€254.7 million), freeing Mission to concentrate … more ➔
M&ALilly buys Europe-rooted AtaiBeckley for up to $3.8BEli Lilly has agreed to acquire AtaiBeckley for up to $3.8 billion (€3.3 billion), turning a psychedelic drug developer built from German and British roots into one of the sector’s largest pharmaceutical … more ➔
intellectual propertySanofi joins the mRNA vaccine patent warsSanofi has sued Pfizer and Moderna, alleging that their COVID-19 and respiratory syncytial virus (RSV) vaccines infringe patents covering the delivery of messenger RNA using lipid nanoparticles it acquired … more ➔
Samsung Biologics
